BBH
VanEck Biotech ETF
Price Chart
Latest Quote
$254.15
+5.28 (+2.12%)
Current Price
| Previous Close | $248.87 |
| Open | $248.40 |
| Day High | $254.15 |
| Day Low | $248.40 |
| Volume | 3,796 |
Fund Information
| Quarterly Dividend / Yield | N/A / 0.39% |
| Net Assets | $487.74M |
| Expense Ratio | 0.35% |
| Category | Health |
| Fund Family | VanEck |
| Net Asset Value | $249.68 |
| Premium/Discount | 1.79% |
| Quarterly Dividend Yield | 0.39% |
| P/E Ratio | 29.97 |
| Exchange | NGM |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $242.81 |
| SMA50 | $240.37 |
| SMA200 | $206.04 |
| RSI | 71.09 |
| ATR | 4.9318 |
| Rel Volume | 0.33 |
Performance History
| Week | +1.47% |
| Month | +3.46% |
| Quarter | +22.18% |
| 6 Months | +39.53% |
| YTD | +33.60% |
| Year | +43.42% |
| 3 Years | +73.18% |
| 5 Years | +32.68% |
| 10 Years | +154.77% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-28 | $254.15 | 3,796 |
| 2026-10-27 | $249.80 | 6,500 |
| 2026-10-26 | $247.39 | 12,800 |
| 2026-10-23 | $246.57 | 4,900 |
| 2026-10-22 | $248.41 | 17,500 |
| 2026-10-21 | $250.46 | 11,900 |
| 2026-10-20 | $248.78 | 13,300 |
| 2026-10-19 | $241.14 | 18,900 |
| 2026-10-16 | $241.36 | 14,500 |
| 2026-10-15 | $246.49 | 14,200 |
| 2026-10-14 | $241.07 | 10,700 |
| 2026-10-13 | $235.92 | 6,100 |
| 2026-10-12 | $239.22 | 10,200 |
| 2026-10-09 | $240.47 | 10,900 |
| 2026-10-08 | $234.03 | 15,800 |
| 2026-10-07 | $237.87 | 8,200 |
| 2026-10-06 | $236.30 | 16,000 |
| 2026-10-05 | $240.53 | 9,400 |
| 2026-10-02 | $237.45 | 11,600 |
| 2026-10-01 | $238.74 | 14,000 |
| 2026-09-30 | $244.58 | 6,900 |
| 2026-09-29 | $245.64 | 13,100 |
| 2026-09-28 | $245.34 | 10,200 |
About VanEck Biotech ETF
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
đ° Latest News
No news articles available at the moment. Check back later for updates on BBH.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.